Somatuline, a medication used to treat acromegaly and neuroendocrine tumors, is currently under patent protection in the United States. The drug is manufactured by Ipsen Biopharmaceuticals, and its active ingredient is lanreotide.

According to DrugPatentWatch.com, the patent for Somatuline is set to expire in the United States on June 26, 2028 [1]. After this date, generic versions of the drug may become available in the US market. However, it's important to note that the expiration of a patent does not automatically mean that generic versions will be available immediately. The FDA approval process for generics can take some time, and other factors such as manufacturing and marketing can also impact the availability of generic versions.

It's also worth noting that while the patent for Somatuline is set to expire in 2028, Ipsen Biopharmaceuticals may still have market exclusivity for the drug through other mechanisms such as pediatric exclusivity or orphan drug exclusivity.

In summary, based on the information from DrugPatentWatch.com, Somatuline is currently under patent protection in the US and is set to expire in 2028. However, the availability of generic versions of the drug after the patent expiration may depend on various factors, including FDA approval and market exclusivity.

Sources:
[1] DrugPatentWatch.com, "Lanreotide (Somatuline) Patent Expiration & Generic Entry Date," <https://www.drugpatentwatch.com/patent/lanreotide-somatuline/>